Idioma: Inglés
Publicado por Kluwer/Plenum, New York, New York, U.S.A., 2000
ISBN 10: 0306462222 ISBN 13: 9780306462221
Librería: Book Booth, Berea, OH, Estados Unidos de America
EUR 52,33
Cantidad disponible: 1 disponibles
Añadir al carritoHard Cover. Condición: New. New condition. 368 pages.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 55,99
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 57,41
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
EUR 65,17
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 54,38
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 54,37
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 59,37
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: preigu, Osnabrück, Alemania
EUR 95,15
Cantidad disponible: 5 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Human Retroviral Infections | Immunological and Therapeutic Control | Kenneth E. Ugen (u. a.) | Taschenbuch | xxii | Englisch | 2013 | Springer US | EAN 9781475781687 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 164,11
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 164,11
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Idioma: Inglés
Publicado por Springer US, Springer New York, 2013
ISBN 10: 1475781687 ISBN 13: 9781475781687
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 114,36
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established 'cure' for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.
EUR 198,53
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. pp. 392.
EUR 178,14
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leuke.
EUR 234,56
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. pp. 392.
Librería: Revaluation Books, Exeter, Reino Unido
EUR 234,00
Cantidad disponible: 2 disponibles
Añadir al carritoPaperback. Condición: Brand New. 390 pages. 9.25x6.10x0.89 inches. In Stock.
Librería: Mispah books, Redhill, SURRE, Reino Unido
EUR 246,45
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback. Condición: Like New. Like New. book.
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 247,94
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. Neuware - The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established 'cure' for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
EUR 58,34
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
EUR 54,95
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
EUR 106,99
Cantidad disponible: 2 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established 'cure' for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability. 392 pp. Englisch.
Librería: moluna, Greven, Alemania
EUR 136,16
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leuke.
Idioma: Inglés
Publicado por Springer US, Springer New York Mär 2013, 2013
ISBN 10: 1475781687 ISBN 13: 9781475781687
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
EUR 160,49
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established ¿cure¿ for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 392 pp. Englisch.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 221,20
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand pp. 392 Illus.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 221,50
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND pp. 392.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 242,28
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand pp. 392 49:B&W 6.14 x 9.21 in or 234 x 156 mm (Royal 8vo) Perfect Bound on White w/Gloss Lam.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 245,58
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND pp. 392.